Adrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Adrian Senderowicz sold 27,000 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $91,800.00. Following the sale, the director now owns 27,000 shares of the company's stock, valued at $91,800. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Puma Biotechnology Price Performance

PBYI traded down $0.02 during midday trading on Tuesday, hitting $3.43. The company had a trading volume of 210,811 shares, compared to its average volume of 443,805. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. The company has a market capitalization of $170.23 million, a PE ratio of 4.45 and a beta of 1.29. Puma Biotechnology, Inc. has a twelve month low of $2.23 and a twelve month high of $4.13. The firm's 50-day simple moving average is $3.20 and its 200-day simple moving average is $3.12.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in Puma Biotechnology by 167.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 6,351 shares in the last quarter. Graham Capital Management L.P. acquired a new stake in shares of Puma Biotechnology during the 4th quarter worth approximately $33,000. ProShare Advisors LLC acquired a new stake in shares of Puma Biotechnology during the 4th quarter worth approximately $36,000. C2C Wealth Management LLC acquired a new stake in shares of Puma Biotechnology during the 4th quarter worth approximately $37,000. Finally, Causeway Capital Management LLC acquired a new stake in shares of Puma Biotechnology during the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 61.29% of the company's stock.

Wall Street Analysts Forecast Growth

PBYI has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.